NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to analysts' expectations of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. NeoGenomics's revenue was up 51.5% compared to the same quarter last year. During the same period last year, the business earned $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

7 brokerages have issued 12-month price objectives for NeoGenomics' shares. Their forecasts range from $14.00 to $35.00. On average, they anticipate NeoGenomics' stock price to reach $24.67 in the next year. This suggests that the stock has a possible downside of 27.0%. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News headlines about NEO stock have trended negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NeoGenomics earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 6,920,000 shares, an increase of 9.1% from the December 15th total of 6,340,000 shares. Based on an average trading volume of 678,300 shares, the short-interest ratio is currently 10.2 days. Currently, 7.0% of the company's stock are sold short. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Varian Medical Systems (VAR), Alnylam Pharmaceuticals (ALNY), DENTSPLY SIRONA (XRAY), Bausch Health Companies (BHC), Universal Health Services (UHS), Steris (STE), GALAPAGOS NV/S (GLPG), Fisher & Paykel Healthcare (FPH), Insulet (PODD), Elanco Animal Health (ELAN), EXACT Sciences (EXAS), West Pharmaceutical Services (WST), Mylan (MYL), Bio-Rad Laboratories (BIO.B) and Bio-Rad Laboratories (BIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), Marvell Technology Group (MRVL), NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Canopy Growth (CGC), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Amarin (AMRN).

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.35%), Summit Creek Advisors LLC (0.35%), Norris Perne & French LLP MI (0.33%), New York State Teachers Retirement System (0.14%), Strs Ohio (0.13%) and Falcon Point Capital LLC (0.08%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Arizona State Retirement System, SG Americas Securities LLC, Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, HWG Holdings LP, Miles Capital Inc., OLD National Bancorp IN, Sciencast Management LP, Norris Perne & French LLP MI and Exchange Traded Concepts LLC. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $33.78.

NeoGenomics has a market capitalization of $3.53 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]